Investigators from Fujian Medical University Release New Data on Cancer Gene Therapy (The co-localization of HBx and COMM upregulates COX-2 promoting HepG2 cell growth)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology have been published. According to news reporting out of Fujian, People's Republic of China, by NewsRx editors, research stated, "HBx is a multifunctional regulator that interacts with host factors to contribute to the development of hepatocellular carcinoma. In this study, to explore the co-localization of HBx and COXIII in HepG2 cells and to investigate the molecular mechanism of HBx in HepG2 cell growth promotion, we first constructed a HepG2 cell line stably expressing the HBx gene in vitro by lentivirus vectors."
Our news journalists obtained a quote from the research from Fujian Medical University, "In addition, we found that HBx co-localized with the inner mitochondrial protein, COXIII, in HepG2 cells by confocal laser scanning microscopy. It led to changes of mitochondrial biogenesis and morphology, including upregulation of COXIII protein expression, increased cytochrome c oxidase activity and higher mitochondrial membrane potential. The upregulation of COX-2 caused by HBx through generation of mitochondrial reactive oxygen species promoted cell growth. Thus, we conclude that co-localization of HBx and COXIII leads to upregulation of COX-2 that promotes HepG2 cell growth."
According to the news editors, the research concluded: "Such a mechanism provides deeper insights into the molecular mechanism of HBV-associated hepatocellular carcinoma."
For more information on this research see: The co-localization of HBx and COMM upregulates COX-2 promoting HepG2 cell growth. International Journal of Oncology, 2014;45(3):1143-1150. International Journal of Oncology can be contacted at: Spandidos Publ Ltd, Pob 18179, Athens, 116 10, Greece (see also Biotechnology).
Our news journalists report that additional information may be obtained by contacting B.Y. Zheng, Fujian Med Univ, Affiliated Hosp 3, Dept. of Gastroenterol, Fuzhou 350108, Fujian, People's Republic of China. Additional authors for this research include X.F. Fang, L.Y. Zou, Y.H. Huang, Z.X. Chen, D. Li, L.Y. Zhou, H. Chen and X.Z. Wang.
Keywords for this news article include: Asia, Biotechnology, Fujian, Cancer Gene Therapy, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC